Recombinant Vaccine Vectors for Neurodegenerative Diseases, Cancer, Autoimmune Disorders, and Respiratory Diseases

This inventive concept leverages the core technology of recombinant vaccine vectors to develop novel treatments for neurodegenerative diseases, cancer, autoimmune disorders, and respiratory diseases, expanding the original patent's malaria-focused application to new therapeutic areas.

The original patent disclosed recombinant vaccine vectors for generating an immune response to malaria. However, there remains a need for effective treatments for various diseases beyond malaria. This inventive concept addresses this limitation by adapting the core technology to tackle distinct disease categories.

The inventive concept involves using recombinant vaccine vectors to express specific proteins or antigens relevant to each disease category. For neurodegenerative diseases, the vectors express neuroprotective proteins like beta-amyloid, tau protein, or alpha-synuclein. For cancer, the vectors express tumor-associated antigens like HER2, BRAF, or p53. For autoimmune disorders, the vectors express tolerogenic proteins like Foxp3, CTLA-4, or PD-1. For respiratory diseases, the vectors express respiratory virus antigens like influenza hemagglutinin, respiratory syncytial virus F protein, or human metapneumovirus F protein. The vectors are designed to stimulate an immune response, preventing or treating the respective diseases.

The new claims introduce a novel application of the recombinant vaccine vector technology, shifting the focus from malaria to distinct disease categories. This inventive concept's novelty lies in the specific combinations of vectors and expressed proteins, which are non-obvious extensions of the original patent.

Alternative embodiments may include using different vector platforms, modifying the expressed proteins, or combining multiple proteins to enhance efficacy. Variations may also involve targeting specific disease subtypes or using the vectors in combination with other therapies.

This inventive concept has significant commercial potential in the pharmaceutical and biotechnology industries, targeting large markets for neurodegenerative diseases, cancer, autoimmune disorders, and respiratory diseases. The adapted technology can be licensed or partnered with companies specializing in these therapeutic areas, generating revenue through royalties, partnerships, or product sales.